Kolexia
Moreau Lionel Oncologie médicale
Moreau Lionel
Oncologie médicale
Selarl Oncodomes
Clermont-Ferrand, France
32 Activités
0 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Tumeurs du sein Tumeurs colorectales Paronychie Folliculite Métastase tumorale Lésions encéphaliques {{person.topmesh8.name}} {{person.topmesh9.name}} {{person.topmesh10.name}}

Collaborateurs

Voir plus
Dalloz Pierre
Dalloz Pierre
Selarl Oncodomes, Clermont-Ferrand, France
Fleury Joel
Fleury Joel
Selarl Oncodomes, Clermont-Ferrand, France
Schoenig Arnaud
Schoenig Arnaud
Selarl Urorep, Ennezat, France
Spano Jean-Philippe
Spano Jean-Philippe
Hôpital Pitie Salpetriere, Paris, France

Industries

Voir plus
Lilly
9 collaboration(s)
Dernière en 2023
AstraZeneca
8 collaboration(s)
Dernière en 2023
MSD
6 collaboration(s)
Dernière en 2023
IQVIA
5 collaboration(s)
Dernière en 2023

Dernières activités

Voir plus
Efficacy of AI and palbociclib in ER+ HER2- advanced breast cancer patients relapsing during adjuvant tamoxifen: An exploratory analysis of the PADA-1 trial.
2021 ASCO Annual Meeting I   28 mai 2021
PREMIUM: A French prospective multicenter observational study of factors impacting on efficacy and compliance to cetuximab treatment in first-line KRAS wild-type metastatic colorectal cancer.
PloS one   21 décembre 2020
A Study to Assess Preference for Subcutaneous Trastuzumab Treatment in Participants With Human Epidermal Growth Factor Receptor (HER)2-Positive Metastatic Breast Cancer Responding to First-Line Intravenous Trastuzumab for at Least 3 Years: An Open-Label, Randomized, Multicenter Phase III Study in Patients With HER2-Positive Metastatic Breast Cancer Responding to First Line Treatment With Intravenous Trastuzumab for at Least 3 Years and Investigating Patient Preference for Subcutaneous Trastuzumab
Essai Clinique (Roche)   03 septembre 2020
Pathways back to driving after acquired brain injury: Patients do not always follow medical advice!
Annals of physical and rehabilitation medicine   11 novembre 2017
Patients' preference of trastuzumab administration (subcutaneous versus intravenous) in HER2-positive metastatic breast cancer: Results of the randomised MetaspHer study.
European journal of cancer (Oxford, England : 1990)   23 juin 2017
Patient preference of trastuzumab administration (SC versus IV) in HER2-positive metastatic breast cancer: Results of the randomised Metaspher study
Abstract Book of the 41st ESMO Congress (ESMO 2016), 7-11 October 2016, Copenhagen, Denmark   01 octobre 2016
PREMIUM, Observational Study: Factors Impacting on Efficacy and Compliance to Cetuximab Treatment in First Line WT KRAS Metastatic Colorectal Cancer
Essai Clinique (Merck-Serono)   20 décembre 2012
Long-term follow-up of HER2-overexpressing stage II or III breast cancer treated by anthracycline-free neoadjuvant chemotherapy.
Annals of oncology : official journal of the European Society for Medical Oncology   06 août 2010
{{person.lastact9.name}}
{{person.lastact9.jour}}   {{person.lastact9.date}}
{{person.lastact10.name}}
{{person.lastact10.jour}}   {{person.lastact10.date}}